The role of 18F-fluorodeoxyglucose positron emission tomography in the prognostication, diagnosis, and management of thyroid carcinoma

Journal of Thyroid Research

Volumn 2012, Issue , 2012, Pages

  Lang, Brian Hung Hin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; MESSENGER RNA; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER; THYROGLOBULIN;

BRAF GENE; CANCER DIAGNOSIS; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GENE; GENE MUTATION; GLUT1 GENE; HUMAN; INTERMETHOD COMPARISON; METASTASIS; NECK DISSECTION; NEEDLE BIOPSY; NIS GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR SUPPRESSOR GENE; WHOLE BODY IMAGING;

EID: 84872349927     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.1155/2012/198313     Document Type: Review

References (49)

1. Pace L., Nicolai E., Klain M., Salvatore M., Diagnostic value of FDG PET/CT imaging. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 53 5 503 512
2. Wadsak W., Mitterhauser M., markus.mitterhauser@meduniwien.ac.at Basics and principles of radiopharmaceuticals for PET/CT. European Journal of Radiology 2010 73 3 461 469 10.1016/j.ejrad.2009.12.022
3. Fletcher J. W., jwfletch@iupui.edu Djulbegovic B., Soares H. P., Siegel B. A., Lowe V. J., Lyman G. H., Coleman R. E., Wahl R., Paschold J. C., Avril N., Einhorn L. H., Suh W. W., Samson D., Delbeke D., Gorman M., Shields A. F., Recommendations on the use of 18F-FDG PET in oncology. Journal of Nuclear Medicine 2008 49 3 480 508 10.2967/jnumed.107.047787 (Pubitemid 351355215)
4. Newberg A., Alavi A., Reivich M., Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Seminars in Nuclear Medicine 2002 32 1 13 34 (Pubitemid 34112940)
5. Gerber B. L., Ordoubadi F. F., Wijns W., Vanoverschelde J. L. J., Knuuti M. J., Janier M., Melon P., Blanksma P. K., Bol A., Bax J. J., Melin J. A., Camici P. G., Positron emission tomography using 18F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. European Heart Journal 2001 22 18 1691 1701 2-s2.0-0034838003 10.1053/euhj.2000.2585 (Pubitemid 32896369)
6. Joensuu H., Ahonen A., Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. Journal of Nuclear Medicine 1987 28 5 910 914 2-s2.0-0023220384 (Pubitemid 17096461)
7. Lang B. H., Law T. T., The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms. The Oncologist 2011 16 4 458 466 10.1634/theoncologist.2010-0256
8. Feine U., Lietzenmayer R., Hanke J. P., Wöhrle H., Müller-Schauenburg W., 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. Nuklearmedizin 1995 34 4 127 134 2-s2.0-0029355220
9. Jeong H. S., Baek C. H., Son Y. I., Choi J. Y., Kim H. J., Ko Y. H., Chung J. H., Baek H. J., Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clinical Endocrinology 2006 65 3 402 407 2-s2.0-33747338648 10.1111/j.1365-2265.2006.02612.x
10. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Pacini F., Schlumberger M., Sherman S. I., Steward D. L., Tuttle R. M., Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 11 1167 1214 2-s2.0-70449370231 10.1089/thy.2009.0110
11. Pryma D. A., Schöder H., Gönen M., Robbins R. J., Larson S. M., Yeung H. W. D., Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. Journal of Nuclear Medicine 2006 47 8 1260 1266 2-s2.0-33749046302 (Pubitemid 47544877)
12. Bogsrud T. V., Karantanis D., Nathan M. A., Mullan B. P., Wiseman G. A., Kasperbauer J. L., Reading C. C., Hay I. D., Lowe V. J., 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008 18 7 713 719 2-s2.0-47549092154 10.1089/thy.2007.0350 (Pubitemid 352009926)
13. Jeong H. S., Chung M., Baek C. H., Ko Y. H., Choi J. Y., Son Y. I., Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas? Laryngoscope 2006 116 12 2133 2137 2-s2.0-33845499721 10.1097/01.mlg.0000243043. 65560.3f (Pubitemid 44912307)
14. Choi J. W., Yoon Y. H., Yoon Y. H., Kim S. M., Koo B. S., Characteristics of primary thyroid carcinoma with false-negative findings on initial 18F-FDG PET/CT. Annals of Surgical Oncology 2011 18 5 1306 1311 2-s2.0-78649690658 10.1245/s10434-010-1469-2
15. Yun M., Noh T. W., Cho A., Choi Y. J., Hong S. W., Park C. S., Lee J. D., Kim C. K., Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. Journal of Clinical Endocrinology and Metabolism 2010 95 7 3182 3188 2-s2.0-77954890772 10.1210/jc.2009-2091
16. Law T. T., Lang B. H. H., Incidental thyroid carcinoma by FDG-PET/CT: a study of clinicopathological characteristics. Annals of Surgical Oncology 2011 18 2 472 478 2-s2.0-77956070209 10.1245/s10434-010-1287-6
17. Chan D. K., Lang B. H., blang@hkucc.hku.hk Law T. T., Value of fluorodeoxyglucose positron emission tomography in characterizing clinically-significant thyroid carcinomas. Surgical Practice 2011 15 2 34 40 10.1111/j.1744-1633.2011.00538.x
18. Esteva D., Muros M. A., Llamas-Elvira J. M., Jiménez Alonso J., Villar J. M., López De La Torre M., Muros T., Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Annals of Surgical Oncology 2009 16 7 2006 2013 2-s2.0-67649173096 10.1245/s10434-009-0483-8
19. Rivera M., Ghossein R. A., Schoder H., Gomez D., Larson S. M., Tuttle R. M., Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008 113 1 48 56 2-s2.0-47149102563 10.1002/cncr.23515 (Pubitemid 351976385)
20. Ricarte-Filho J. C., Ryder M., Chitale D. A., Rivera M., Heguy A., Ladanyi M., Janakiraman M., Solit D., Knauf J. A., Tuttle R. M., Ghossein R. A., Fagin J. A., Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 2009 69 11 4885 4893 2-s2.0-66349098309 10.1158/0008-5472.CAN-09-0727
21. Robbins R. J., Wan Q., Grewal R. K., Reibke R., Gonen M., Strauss H. W., Tuttle R. M., Drucker W., Larson S. M., Real-time prognosis for metastatic thyroid carcinoma based on 2-(18F)-fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Journal of Clinical Endocrinology and Metabolism 2006 91 2 498 505 2-s2.0-32544437659 10.1210/jc.2005-1534 (Pubitemid 43236915)
22. Deandeis D., Al Ghuzian A., Leboulleux S., Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) pattern of metastatic thyroid cancer correlate with patient outcome. Endocrine-Related Cancer 2011 18 159 169
23. Mitsutake N., Knauf J. A., Mitsutake S., Mesa C. Jr., Zhang L., Fagin J. A., Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research 2005 65 6 2465 2473 2-s2.0-16844367605 10.1158/0008-5472.CAN-04-3314 (Pubitemid 40490159)
24. Romei C., Ciampi R., Faviana P., Agate L., Molinaro E., Bottici V., Basolo F., Miccoli P., Pacini F., Pinchera A., Elisei R., BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer 2008 15 2 511 520 2-s2.0-45849106001 10.1677/ERC-07-0130 (Pubitemid 351880839)
25. Riesco-Eizaguirre G., Rodríguez I., De la Vieja A., Costamagna E., Carrasco N., Nistal M., Santisteban P., The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research 2009 69 21 8317 8325 2-s2.0-70350554104 10.1158/0008-5472.CAN-09-1248
26. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., Barbi F., Avenia N., Scipioni A., Verrienti A., Tosi E., Cavaliere A., Gulino A., Filetti S., Russo D., BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 2007 92 7 2840 2843 2-s2.0-34447134910 10.1210/jc.2006-2707 (Pubitemid 47037399)
27. Ciampi R., Vivaldi A., Romei C., Del Guerra A., Salvadori P., Cosci B., Pinchera A., Elisei R., Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Molecular and Cellular Endocrinology 2008 291 1-2 57 62 2-s2.0-48349138947 10.1016/j.mce.2008.05.003
28. Kresnik E., Gallowitsch H. J., Mikosch P., Stettner H., Igerc I., Gomez I., Kumnig G., Lind P., Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003 133 3 294 299 2-s2.0-0037352949 10.1067/msy.2003.71 (Pubitemid 36390792)
29. 18FDG-PET/CT. Surgery 2005 138 6 1166 1175 2-s2.0-29144461539 10.1016/j.surg.2005.08.031 (Pubitemid 41797359)
30. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. Journal of Nuclear Medicine 2006 47 5 770 775 2-s2.0-33745556546 (Pubitemid 46768439)
31. 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. Journal of Clinical Endocrinology and Metabolism 2007 92 11 4485 4488 2-s2.0-35948990409 10.1210/jc.2007-1043 (Pubitemid 350074775)
32. Hales N. W., Krempl G. A., Medina J. E., Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? American Journal of Otolaryngology 2008 29 2 113 118 2-s2.0-39749158605 10.1016/j.amjoto.2007.04.006 (Pubitemid 351296350)
33. Smith R. B., Robinson R. A., Hoffman H. T., Graham M. M., Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid. OtolaryngologyHead and Neck Surgery 2008 138 1 101 106 2-s2.0-37349057425 10.1016/j.otohns.2007.09.008 (Pubitemid 350299636)
34. Traugott A. L., Dehdashti F., Trinkaus K., Cohen M., Fialkowski E., Quayle F., Hussain H., Davila R., Ylagan L., Moley J. F., Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18f-fluorodeoxyglucose positron emission tomography: interim analysis. World Journal of Surgery 2010 34 6 1247 1253 2-s2.0-77955558143 10.1007/s00268-010-0398-3
35. Vriens D., de Wilt J. H., van der Wilt G. J., Netea-Maier R. T., Oyen W. J., de Geus-Oei L. F., The role of [(18) F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. In press 10.1002/cncr.26085
36. Lang B. H. H., Lo C. Y., Technological innovations in surgical approach for thyroid cancer. Journal of Oncology 2010 2010 6 2-s2.0-77956795029 10.1155/2010/490719 490719
37. Bloom A. D., Adler L. P., Shuck J. M., Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993 114 4 728 735 2-s2.0-0027366898 (Pubitemid 23303322)
38. Utiger R. D., The multiplicity of thyroid nodules and carcinomas. The New England Journal of Medicine 2005 352 23 2376 2378 2-s2.0-20344394212 10.1056/NEJMp058061 (Pubitemid 40958433)
39. Kim J. M., Ryu J. S., Kim T. Y., Won B. K., Gui Y. K., Gong G., Dae H. M., Seong C. K., Suck J. H., Young K. S., 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. Journal of Clinical Endocrinology and Metabolism 2007 92 5 1630 1634 2-s2.0-34249858278 10.1210/jc.2006-2311 (Pubitemid 46997163)
40. Lloyd R. V., Erickson L. A., Casey M. B., Lam K. Y., Lohse C. M., Asa S. L., Chan J. K. C., DeLellis R. A., Harach H. R., Kakudo K., LiVolsi V. A., Rosai J., Sebo T. J., Sobrinho-Simoes M., Wenig B. M., Lae M. E., Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. American Journal of Surgical Pathology 2004 28 10 1336 1340 2-s2.0-5044228266 10.1097/01.pas.0000135519.34847.f6 (Pubitemid 39336372)
41. Gemsenjager E., Perren A., Seifert B., Schüler G., Schweizer I., Heitz P. U., Lymph node surgery in papillary thyroid carcinoma. Journal of the American College of Surgeons 2003 197 2 182 190 2-s2.0-18844471231 10.1016/S1072-7515(03)00421-6 (Pubitemid 36927380)
42. Frilling A., Tecklenborg K., Gorges R., Weber F., Clausen M., Broelsch E. C., Preoperative diagnostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Annals of Surgery 2001 234 6 804 811 2-s2.0-0035209518 10.1097/00000658-200112000-00012 (Pubitemid 33117201)
43. Wang W., Macapinlac H., Larson S. M., Yeh S. D. J., Akhurst T., Finn R. D., Rosai J., Robbins R. J., [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. Journal of Clinical Endocrinology and Metabolism 1999 84 7 2291 2302 2-s2.0-0033237663
44. Lal G., Fairchild T., Howe J. R., Weigel R. J., Sugg S. L., Menda Y., PET-CT scans in recurrent or persistent differentiated thyroid canceris there added utility beyond conventional imaging? Surgery 2010 148 6 1082 1089 2-s2.0-78649920386 10.1016/j.surg.2010.09.015
45. Petrich T., Borner A. R., Otto D., Hofmann M., Knapp W. H., Influence of rhTSH on (18F) fluorodeoxyglucose uptake by differentiated thyroid carcinoma. European Journal of Nuclear Medicine 2002 29 5 641 647 2-s2.0-0036239640 10.1007/s00259-001-0745-6 (Pubitemid 34439324)
46. Moog F., Linke R., Manthey N., Tiling R., Knesewitsch P., Tatsch K., Hahn K., Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. Journal of Nuclear Medicine 2000 41 12 1989 1995 2-s2.0-0034518644 (Pubitemid 32038687)
47. Chin B. B., chin0004@mc.duke.edu Patel P., Cohade C., Ewertz M., Wahl R., Ladenson P., Recombinant human thyrotrophin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2004 89 1 91 95 10.1210/jc.2003-031027 (Pubitemid 38183865)
48. Branstetter B. F. IV, Blodgett T. M., Zimmer L. A., Snyderman C. H., Johnson J. T., Raman S., Meltzer C. C., Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005 235 2 580 586 2-s2.0-17644406392 10.1148/radiol.2352040134 (Pubitemid 40571100)
49. Razfar A., Branstetter B. F. IV, Christopoulos A., Lebeau S. O., Hodak S. P., Heron D. E., Escott E. J., Ferris R. L., Clinical usefulness of positron emission tomographycomputed tomography in recurrent thyroid carcinoma. Archives of OtolaryngologyHead and Neck Surgery 2010 136 2 120 125 2-s2.0-77149135765 10.1001/archoto.2009.215